Moreover, integrating predictive biomarkers (e.g., baseline kynurenine/tryptophan ratios, tumor IDO/TDO expression profiles, and immune cell infiltration patterns) may help stratify patients and improve outcomes in future trials. The gene discussed is TDO2; the disease is neoplasm.